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Abstract 
Objectives; Within HIV positive men having sex with men the epidemic of hepatitis C (HCV) is ongoing. 
Transmission of resistant variants of HCV after failure of treatment with directly acting antivirals (DAA) 
could be a major threat to the effectivity of therapy. We determined whether HCV resistant variants to 
DAAs were prevalent amongst patients with an acute HCV infection diagnosed in 2013 and 2014 in the 
Netherlands. 
Methods: Target enrichment for viral nucleic acid separation and deep sequencing were used to recover 
whole HCV genomes of 50 patients with an acute HCV infection. The genomes were assembled by de 
novo assembly and analysed for known DAA resistance mutations. 
Results: In acute HCV infected treatment-naïve patients the relevant resistance associated substitutions 
were Q80K (40%) in NS3/4a, M28V (24%) and Q30H combined with Y93H (2%) in NS5A and M414T (2%) 
or S556G (2%) in NS5b. Patients who failed on boceprevir, peginterferon and ribavirin therapy developed 
mutations in NS3 at position T54A and R155K. 
Conclusion: Target enrichment and whole genome sequencing was successfully applied directly on 
clinical samples from patients with an acute HCV infection. 
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Introduction 
Since very effective and well-tolerated direct-acting antivirals (DAAs) have become available, hepatitis C 
(HCV) has progressed from a difficult to treat to an almost universally curable infection. Currently, there 
is an urgent need for reliable sequencing techniques to determine whether resistant variants influence 
treatment efficacy. Whole genome sequencing (WGS) directly from clinical samples can contribute 
significantly to the understanding of clinical population structures, including minority populations, mixed 
infections and resistance mutations(1). In this study, we apply the target enrichment approach directly to 
clinical specimens of acute HCV infected patients treated in the Dutch Acute HCV in HIV Study (DAHHS) 
(2). 
 
Materials and Methods 
Baseline samples (initiation of therapy) of acute HCV genotype 1 infected patients were available from 
50 patients participating in the DAHH-Study (supplementary table S1). Two patients with a poor 
response to therapy at week 4 (above 1000 IU/ml) and three patients who relapsed after treatment were 
analyzed for acquired resistance. The total number of samples analyzed was 55. 
 
Double stranded cDNA synthesis 
Nucleic acid was extracted from EDTA plasma using the DSP Virus/Pathogen kit on the QiaSymphony 
with the complex200 protocol and nucleic acid was eluted in 60ul. RNA was concentrated to ~11 µl and 
the complete sample was used for first strand cDNA synthesis (Superscript III Reverse Transcriptase kit, 
Life Technologies). Second strand cDNA synthesis used 20 µl from the first stand synthesis (Second 
Strand cDNA synthesis kit, NEB). All of the ds cDNA was purified (Genomic DNA clean and concentrator 
TM kit, Zymo Research) eluting in 30 µl of ultrapure nuclease free H2O.  
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SureSelectXT Target Enrichment: Library preparation, hybridisation and enrichment  
The purified ds cDNA were quantified using the Qubit (dsDNA HS assay kit, Life Technologies) and 200-
500 ng of ds cDNA was sheared for 150 seconds, using a Covaris E220 focused ultra-sonication system 
(PIP 175, Duty factor 5, Cycles per Burst 200). End-repair, adapter ligation, hybridisation, PCR (12 cycles 
pre-capture and 18 or 22 cycles post capture) and all post- reaction clean-up steps were performed 
according to the SureSelectXT Automated Target Enrichment for Illumina Paired-End Multiplexed 
Sequencing 200 ng protocol (version F.2) on the Bravo platform WorkStation B from Agilent 
Technologies. The 120-mer RNA baits spanning the length of 953 GenBank HCV partial and complete 
reference genomes were designed using an in-house PERL script developed by the PATHSEEK consortium 
and synthesised by Agilent Technologies. The samples were sequenced in multiple runs on an Illumina 
MiSeq sequencing platform with 500 bp v2 reagent sets.  
 
Sequence data analysis 
Genome mapping, assembly and finishing was performed using CLC Genomics Workbench (version 
7.5/7.5.1) including the CLC Microbial Genome Finishing Module (version 1.4) from Qiagen. Trimmed 
reads were pre-filtered against a GenBank reference list containing 953 partial and complete HCV 
genomes and a subset of 50,000-100,000 HCV specific reads were subsampled and used for de novo 
assembly. Reference based mapping, using the best matching GenBank HCV reference and high 
stringency affinity gap cost was performed for samples failing de novo assembly.  
Positions of interest for DAA resistance (see tables S2-S4 in supplementary material) were identified in 
the GenBank reference HCV strain H77 (accession no. AF011751). All trimmed reads were mapped 
against the genes of interest (NS3/NS4a, NS5a and NS5b) using the default affine gap cost parameters 
followed by removal of duplicated mapped reads. Low frequency variant detection was called with a 
min. coverage filter of 20x and a min. count of 5 independent reads. A relative read direction filter was 
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used and variants with a read direction distribution significantly different from the expected were 
removed.  
 
Results 
Result of whole genome sequencing 
In this study we performed WGS directly on clinical specimens from 55 HCV positive samples. Using de 
novo assembly, we generated complete genomes (>90-100% recovery of the HCV genome) from 51 
samples, partial genomes (>80-90% recovery of the HCV genome) from 3 samples and 1 low titre sample 
(3070 IU/ml) failed to generate a HCV genome (<50% recovery of the HCV genome) (table S5 in 
supplementary material). Overall, the sequence data showed strong correlation between the number of 
HCV copies in the diagnostic sample and the mean read depth across the genome (Pearson correlation 
coefficient 0.39 P=0.005). From this data-set, the lower limit of detection for WGS of HCV directly from 
clinical samples was estimated to a diagnostic value of ~3500 IU/ml (figure 1). 
 
Four samples (Ol12, Na01, Ad04, Ef06) failed de novo assembly despite having >90% on-target reads 
(reads mapping to HCV). Reference based mapping showed, from the highly variable region of the HCV 
E2 region (H77 numbering 872-1968), an inter-subtype (GT1A plus GT1A) dual infection in patient 
Ol12(data not shown). Due to lack of sample material this could however not be confirmed using 
classical techniques for detecting dual infection. A second consensus sequence could not be recovered 
from patient Na01 and Ad04 indicating that these patients did not have a dual infection. The two 
consensus sequences recovered from patients Ef06 rooted very close to each other in a phylogenetic 
tree, suggesting strain variation rather than dual infection within the patient.  
 
Directly Acting Antivirals (DAAs) resistance analysis 
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In the DAHHS cohort DAA resistant associated substitutions (RASs) were identified in 31 of the 50 
baseline samples. In 38.7% (12/31) of the samples a single DAA RASs was identified and in 61.3% (19/31) 
multiple RASs were detected. The most prominent RAS in NS3 was Q80K in 40% (20/50) of the samples. 
In the NS5a region, M28V 24% (12/50) and H58P 26% (13/50) were found as dominant. The A421V 22% 
(11/50) and I585V 12% (6/50) were seen as most occurring RASs in the NS5b region (Figures 2 a/b/c). 
Remarkably, in patient Me05, an uncommon combination of Q30H and Y93H in NS5a occurred. This 
combination is associated with 93.136 fold resistance in EC50 against daclatasvir (3). Additional results of 
treatment failures are discussed in the supplements.   
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Discussion 
In this study we used the combination of whole-genome enrichment and deep sequencing to recover 
close to complete genomes for 98% of the sample set. We used the sequence data to assess the 
prevalence of known DAA resistance mutations within the acute HCV genotype 1 infected patients and 
fortunately, between 2013 and 2014 no convincing evidence of transmitted drug resistance was found. 
However, in high-risk groups with ongoing transmission, HCV treating physicians should remain aware of 
circulating DAA resistant variants when treatment failure is observed. 
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Figure 1 Relationship between mean read depth across the whole genome and the diagnostic viral 
load 
 
 
Legend figure 1. Figure 1 shows the relationship between the HCV copy number identified in the 
diagnostic sample (IU/ml x 2.7 = copies/ml) and the mean read depth obtained across the whole HCV 
genome.  
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Figure 2 Baseline resistance 
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Figure 2 illustrates the known DAA resistance associated mutation identified at baseline (n=50) in the 
acute HCV cohort. The vertical axis shows the proportion of patients (in percentage) in which the different 
mutations were identified. a) Known DAA resistance associated mutations in NS3/NS4a, b) Known DAA 
resistance associated mutations in NS5a and c) Known DAA resistance associated mutations in NS5b.   
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Supplements 
 
Development of RASs during therapy 
 
Insufficient response at week 4 of therapy 
Patient Ad04 was diagnosed with genotype 1a and had a baseline HCV viral load of 16.9x106 IU/ml.  At 
week 4 the patient presented with a viral load of 23.1x106 IU/ml and reported that he had discontinued 
therapy one week before. BOC resistance associated mutations were not identified in patient Ad04 at 
the two sampling points. Surprisingly, based on the sequence results this patient turned out to have a 
genotype 4 infection at both time points instead of the genotype 1. 
 
Patient On14 was diagnosed with genotype 1a with a baseline viral load of 16.4x106 IU/ml. At week four 
of treatment he had a viral load of 5790 IU/ml and reported to be treatment adherent. No baseline DAA 
RASs were detected, but after four weeks of therapy 2 BOC associated mutations (T54A and R155K) were 
identified at 53.3% and 14% variant frequencies, that result in a 10-fold decrease in BOC susceptibility 
(Tong et al, Biochemistry). 
 
Relapse 12 weeks after treatment 
Patient Ec03 was treated for 12 weeks and had an undetectable HCV RNA at week 4, but became 
detectable at week 12 after treatment. The baseline and week 12, post-treatment samples showed two 
different HCV genotype 1a strains. Second best reference approach showed that the genotype present at 
failure was not detected at baseline (data not shown). Therefore, WGS proved that this patient did not 
have a relapse but a reinfection. 
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Patient Md04 (genotype 1b) and Oe05 (genotype 1a) were successfully treated for 12 weeks. Both had a 
detectable viral load at week 4 of treatment but became negative at week 8. Both patients became 
detectable at week 12 after therapy and strains in both cases were identical to the baseline strains. At 
the time of relapse, patient Oe05 showed a R155K dominant (92%) mutation in the NS3 region, which is 
associated with major BOC resistance. In contrast, Md04 had no known acquired BOC mutations at 
relapse but was positive for the I132V RASs in the NS3 region at baseline. 
 
Supplementary table S1. Baseline characteristics 
 
n=50     
male   100%   
 age years 40 (33-47) 
 genotype 1 a 98% 
  
 
b 2% 
  HCV viral load IU/ml 439.500 (40.450-2.362.500) 
Cd4 E6/mL  650 (450-833) 
 Il 28B genotype 
    CC 
 
38% 
  non-CC 
 
54% 
  unknown  8%   
 
Table S1 Legend. Characteristics of patients analysed at initiation of treatment.  All results are presented 
as median with interquartile range or as percentage. 
 
Table S2. Mutations known to be associated with resistance in NS3/NS4a 
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Amino acid 
position (per 
gene) 
Sensitive aa 
Amino acid 
in ref. H77 1a  
AF011751 
3-letter code 
in H77 
Resistant aa 
36 V V Val M/L 
41 Q Q Gln R/N/L/K/H 
43 F F Phe V/S/L/I 
54 T T Thr S/A 
55 V V Val I/A 
56 Y Y Tyr H 
80 Q Q Gln R/N/L/K/H 
95 T T Thr S 
109 R R Arg K 
122 S S Ser S/R/N/G/A 
132 I I Ile V 
155 R R Arg W/T/S/Q/M/K/G 
156 A A Ala V/T/S/N/G/F 
168 D D Asp Y/N/I/H/G/E/A 
170 V I Ile A 
Legend table S2. Table S2 lists the known DAA resistance associated mutations in NS3/NS4a which was 
assessed in this study. 
 
Table S3. Mutations known to be associated with resistance inNS5a 
17 
 
Amino acid 
position (per 
gene) 
Sensitive aa 
Amino acid 
in ref. H77 
1a  
AF011751 
3-letter code 
in H77 
Resistant 
aa 
28 M/L M Met V/T 
30 R/Q Q Gln E/H/Q/R 
31 L L Leu F/M/V 
37 V V Val M 
58 H H His P 
93 Y Y Tyr C/H/N 
Legend table S3. Table S3 lists the known DAA resistance associated mutations in NS5a which was 
assessed in this study. 
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Table S4. Mutations known to be associated with resistance in NS5b 
Amino acid 
position (per 
gene) 
Sensitive aa 
Amino acid 
in ref. H77 1a  
AF011751 
3-letter code 
in H77 
Resistant aa 
282 S S Ser T 
316 C C Cys Y/N 
365 S S Ser ? 
368 S S Ser T 
395 A A Ala G 
411 N N Asn S 
414 M M Met T 
419 L L Leu S 
421 A A Ala V 
422 R R Arg K 
423 M M Met V/T 
444 N N Asn K 
445 C C Cys F/N/G 
448 Y Y Tyr H/C 
451 C C Cys S/R 
482 I I Ile L 
486 A A Ala V 
494 V V Val ? 
495 P P Pro S/L 
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496 P P Pro ? 
499 V A Ala ? 
553 A A Ala V 
556 S S Ser F/N/G 
559 D D Asp G 
565 S S Ser F 
585 I I Ile V 
Legend table S4. Table S4 lists the known DAA resistance associated mutations in NS5b which was 
assessed in this study. 
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Table S5. Overview of sequence results  
Patient 
ID 
Diagnostic 
value 
IU/ml 
Note 
Total no. of 
reads 
On-target 
reads 
(%) 
Coverage 
of ref. (%) 
Mean read 
depth 
Consensus 
Sequence (bp) 
length 
Out-come 
Eb02 9.55E+04 baseline 642,798 69.24 89.02 2,060.07 8546 partial 
Ec03 5.24E+05 baseline 1,480,434 95.46 97.93 8,426.85 9401 complete 
Ed04 1.67E+06 baseline 1,237,426 95.33 97.75 10,976.69 9384 complete 
Ee05 4.87E+07 baseline 1,227,084 97.34 98.43 14,376.27 9449 complete 
Ef06 1.91E+07 baseline 1,078,260 96.63 96.85 19,075.34 9298 complete 
Eh08 1.00E+07 baseline 1,305,908 96.89 97.63 12,147.69 9372 complete 
Ei09 8.13E+05 baseline 1,249,624 89.5 97.72 6,812.59 9381 complete 
ma01 5.95E+05 baseline 892,498 72.53 96.82 5,331.41 9295 complete 
Na01 6.85E+05 baseline 1,035,510 96.06 97.09 20,855.58 9321 complete 
Oa01 4.27E+04 baseline 634,808 92.45 92.97 2,987.47 8587 complete 
Ra01 1.20E+04 baseline 285,792 47.59 92.69 484.47 8898 complete 
Oc03 1.05E+04 baseline 1,157,600 90.71 98.20 9,595 9427 complete 
Of06 1.43E+04 baseline 821,494 42.25 98.10 2,485 9418 complete 
Od04 3.38E+05 baseline 1,239,850 92.93 98.30 10,985 9437 complete 
Ob02 8.06E+06 baseline 1,343,942 70.57 98.33 14,385 9440 complete 
Og07 8.08E+04 baseline 928,300 39.4 91.39 2,863 8773 complete 
Oe05 1.27E+07 baseline 1,033,120 94.9 86.10 14,460 8266 partial 
Aa01 2.81E+05 baseline 1,459,442 93.39 98.17 15,485 9424 complete 
Ab02 6.03E+06 baseline 918,110 93.33 98.28 10,985 9435 complete 
Ek11 1.07E+05 baseline 904,798 67.98 98.02 6,056 9410 complete 
Em13 1.61E+05 baseline 1,104,180 83.41 99.15 9,612 9518 complete 
Eo15 2.31E+07 baseline 1,036,060 92.87 97.60 13,013 9370 complete 
Ep16 2.80E+07 baseline 1,084,814 94.28 98.00 12,755 9408 complete 
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Eq17 2.65E+05 baseline 1,305,270 81.85 98.02 9,250 9410 complete 
Es19 5.23E+06 baseline 896,744 87.2 97.73 10,045 9382 complete 
Ea01 7.49E+05 baseline 1,577,244 94.03 95.11 15,671 9131 complete 
Ac03 9.81E+04 baseline 947,992 85.39 97.74 6,508 9383 complete 
Ad04 1.69E+07 baseline 870,658 89.66 96.86 12,099 9299 complete 
Ae05 3.10E+05 baseline 829,314 87.15 98.53 5,587 9459 complete 
Af06 6.71E+04 baseline 1,079,900 91.65 96.00 9,890 677, 4366, 4174 complete 
Ag07 5.55E+04 baseline 1,037,550 81.82 97.79 4,345 9388 complete 
Mc03 9.40E+07 baseline 934,552 95.53 98.19 11,596 9426 complete 
Md04 1.21E+05 baseline 911,260 89.46 98.04 5,864 9412 complete 
Me05 4.52E+06 baseline 1,002,154 91.98 97.79 7,637 9388 complete 
Mf06 2.51E+04 baseline 1,019,344 94.08 98.15 8,227 9422 complete 
On14 1.64E+07 baseline 898,712 96.92 96.42 11,054 7643, 1613 complete 
Op16 1.00E+07 baseline 789,490 94.68 90.65 10,643 
599, 2702, 2309, 
3093, 
complete 
Oq17 1.07E+04 baseline 594,852 20.25 88.75 572 7595, 925 partial 
Os19 2.36E+06 baseline 1,014,772 92.6 98.59 11,406 9465 complete 
Ot20 2.66E+06 baseline 875,084 95.74 97.99 10,521 9407 complete 
Ec03 5.04E+05 week 24 926,832 91.63 94.00 7,208 9024 complete 
Oe05 3.90E+06 week 24 1,250,586 97.19 97.97 12,173 9405 complete 
Sc03 8.59E+04 baseline 716,228 96.14 97.68 3,716 9377 complete 
Sd04 2.40E+05 baseline 1,022,048 92.17 97.92 6,415 9400 complete 
Ua01 1.32E+07 baseline 1,006,068 97.52 98.02 12,330 9410 complete 
Ub02 1.01E+07 baseline 2,075,844 92.81 98.13 18,395 9420 complete 
Uc03 7.10E+05 baseline 1,530,604 94.73 97.85 11,909 9394 complete 
Ad04 2.30E+07 week 4 979,162 96.94 96.86 19,789.72 9299 
complete 
 
Md04 2.14E+05 week 24 956,070 94.4 93.70 4,688 9383 complete 
On14 5.79E+03 week 4 638,858 15.77 93.70 364 9205 complete 
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Ol12 4.58E+03 baseline 2,410,436 30.97 95.97 16,081 9214 complete 
En14 3.73E+03 baseline 3,607,426 6.58 95.86 1,448.10 9203 complete 
Ou21 6.00E+03 baseline 2,135,530 28.53 96.36 4,308.14 9251 complete 
Eg07 8.59E+03 baseline 1,942,860 10 91.20 1,520.65 8755 complete 
El12 3.07E+03 baseline 1,799,658 0.78 31.00 0.92 - fail 
Legend table S5 .The column on-target reads (%) refers to the proportion of the total number of reads 
from each sample mapping to HCV. Coverage of ref. (%) is the fraction of the HCV genome recovered 
from the WGS and is estimated from the consensus sequence (bp) length divided by 9600 (bp), which is 
an approximated size of the HCV genome.  The mean read depth is the average sequence coverage across 
the genome. Sequence outcome is defined as complete when >90-100% of the HCV genome is recovered 
(coverage of ref.), partial when >80-90% of the HCV genome is recovered and fail when <50% of the HCV 
genome is recovered. 
 
